Investing in Medicine

Aescap Life Sciences is a biotech fund that invests in publicly traded biotech companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and/or medical devices. The fund operates under a full AIFM license and is managed by an experienced team with a great track record. Read more about the impact the fund has on the daily lives of millions of people and how it delivers good financial returns.

The Biotech market

The biotech sector, also known as the life sciences sector, is a large and fast growing sector driven on the one hand by a globally aging population and the need for western medicine in emerging markets. On the other hand, the biotech sector is driven by innovation which has taken big leaps in recent years in areas such as RNA, gene and cell therapies. With more than 800 public biotech companies it requires quite some expertise to navigate the investment landscape and find derisked companies with a high earning power that are still undervalued.

Get acquainted

Our monthly presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on October 14th at 15.00 cet.

Meet the team

The Aescap team, led by Portfolio Manager Patrick Krol, consists of experienced professionals with different backgrounds playing an essential role in the performance of the fund. With 5 full-time employees, 4 advisors, and 17 medical field experts, the Aescap team creates a portfolio of successful biotech companies that not only provide a good financial return but contribute to improving the well-being of patients through their groundbreaking medicine.


Want to stay up to date?
Subscribe to our newsletter here.

    Latest News

    Sustainability at Aescap

    Since its inception, Aescap has taken environmental, social and governance (ESG) factors into consideration by analyzing sustainability impact of its portfolio companies and potential new investments. By continuously doing so, Aescap aims to encourage companies in our sector to act with the well-being of people and our planet in mind. The fund focuses its investments

    Aescap Life Sciences Quarterly Update Q2 2021

    The fund finished the second quarter with a strong performance in June of +7,1%. Several portfolio companies presented positive news, as is further detailed in the company highlights section below.

    Facts & Figures – RNA Therapeutics

    Innovation in the medical field has strongly accelerated in the last century and we see it continuing at an even higher pace going forward. In this technology showcase we will highlight one of the most advanced of such technologies, RNA therapeutics. We will describe the rationale behind this technology, as well as its strength and